{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:17:24Z","timestamp":1793222244969,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T00:00:00Z","timestamp":1583107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004751","name":"Chinese Ministry of Science and Technology | Department of S and T for Social Development","doi-asserted-by":"publisher","award":["2016YFA0101000, 2016YFA0101002, 2016YFA0101003, 2018YFA0109800"],"award-info":[{"award-number":["2016YFA0101000, 2016YFA0101002, 2016YFA0101003, 2018YFA0109800"]}],"id":[{"id":"10.13039\/501100004751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nowadays, immune diseases are a large burden in healthcare. Mesenchymal stem cells (MSCs) have prominent ability in immunomodulation and have been applicated on treating many immune-related diseases. However, the clinical outcomes can be disparate and sometimes completely counterproductive beyond explanation of cell heterogeneity. The theory of immunomodulation plasticity in MSCs has then emerged to explain that MSCs can be induced into proinflammatory MSC1 or anti-inflammatory MSC2 responding to different immune environment. It would be safer and more efficient if we could induce MSCs into a certain immune phenotype, in most cases MSC2, prior to medical treatment. In this study, we screened and identified a classical FDA-approved drug, chlorzoxazone (CZ). Unlike traditional method induced by IFN-\u03b3, CZ can induce MSC into MSC2 phenotype and enhance the immunosuppressive capacity without elevation of immunogenicity of MSCs. CZ-treated MSCs can better inhibit T cells activation and proliferation, promote expression of IDO and other immune mediators in vitro, and alleviate inflammatory infiltration and tissue damage in acute kidney injury rat model more effectively. Moreover, we discovered that CZ modulates phosphorylation of transcriptional factor forkhead box O3 (FOXO3) independent of classical AKT or ERK signaling pathways, to promote expression of downstream immune-related genes, therefore contributing to augmentation of MSCs immunosuppressive capacity. Our study established a novel and effective approach to induce MSC2, which is ready for clinical application.<\/jats:p>","DOI":"10.1038\/s41419-020-2357-8","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T09:08:51Z","timestamp":1583140131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation"],"prefix":"10.1038","volume":"11","author":[{"given":"Luchan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9536-287X","authenticated-orcid":false,"given":"Xueyuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Chunhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,2]]},"reference":[{"key":"2357_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev-bioeng-071516-044603","volume":"19","author":"EA Scott","year":"2017","unstructured":"Scott, E. A., Karabin, N. B. & Augsornworawat, P. Overcoming immune dysregulation with immunoengineered nanobiomaterials. Annu Rev. Biomed. Eng. 19, 57\u201384 (2017).","journal-title":"Annu Rev. Biomed. Eng."},{"key":"2357_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/0963689717743512","volume":"27","author":"L Andrade","year":"2018","unstructured":"Andrade, L., Rodrigues, C. E., Gomes, S. A. & Noronha, I. L. Acute kidney injury as a condition of renal senescence. Cell Transpl. 27, 739\u2013753 (2018).","journal-title":"Cell Transpl."},{"key":"2357_CR3","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579\u20131586 (2008).","journal-title":"Lancet"},{"key":"2357_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.berh.2010.01.008","volume":"24","author":"A Tyndall","year":"2010","unstructured":"Tyndall, A. & van Laar, J. M. Stem cells in the treatment of inflammatory arthritis. Best. Pract. Res. Clin. Rheumatol. 24, 565\u2013574 (2010).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"2357_CR5","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun, L. et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 62, 2467\u20132475 (2010).","journal-title":"Arthritis Rheum."},{"key":"2357_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000449091","volume":"35","author":"GM Forbes","year":"2017","unstructured":"Forbes, G. M. Mesenchymal stromal cell therapy in Crohn's disease. Digestive Dis. 35, 115\u2013122 (2017).","journal-title":"Digestive Dis."},{"key":"2357_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00937-2","volume":"8","author":"L Perico","year":"2017","unstructured":"Perico, L. et al. Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat. Commun. 8, 983 (2017).","journal-title":"Nat. Commun."},{"key":"2357_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1152\/physrev.00019.2015","volume":"96","author":"S Golpanian","year":"2016","unstructured":"Golpanian, S., Wolf, A., Hatzistergos, K. E. & Hare, J. M. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol. Rev. 96, 1127\u20131168 (2016).","journal-title":"Physiol. Rev."},{"issue":"Suppl 2","key":"2357_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","volume":"27","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z. et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J. Gastroenterol. Hepatol. 27 (Suppl 2), 112\u2013120 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2357_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.stem.2008.01.007","volume":"2","author":"A Keating","year":"2008","unstructured":"Keating, A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell 2, 106\u2013108 (2008).","journal-title":"Cell Stem Cell"},{"key":"2357_CR11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726\u2013736 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"2357_CR12","first-page":"824","volume":"4","author":"R Romieu-Mourez","year":"2012","unstructured":"Romieu-Mourez, R., Coutu, D. L. & Galipeau, J. The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies. Front Biosci. (Elite Ed.) 4, 824\u2013837 (2012).","journal-title":"Front Biosci. (Elite Ed.)"},{"key":"2357_CR13","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ejhf.898","volume":"19","author":"JR Teerlink","year":"2017","unstructured":"Teerlink, J. R. et al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the congestive heart failure cardiopoietic regenerative therapy (CHART-1) study. Eur. J. Heart Fail. 19, 1520\u20131529 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"2357_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1365-2249.2009.04069.x","volume":"159","author":"B Chen","year":"2010","unstructured":"Chen, B. et al. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin. Exp. Immunol. 159, 292\u2013302 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"2357_CR15","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/sj.leu.2404489","volume":"21","author":"R Ramasamy","year":"2007","unstructured":"Ramasamy, R. et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21, 304\u2013310 (2007).","journal-title":"Leukemia"},{"key":"2357_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1084\/jem.20051921","volume":"203","author":"AY Khakoo","year":"2006","unstructured":"Khakoo, A. Y. et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med 203, 1235\u20131247 (2006).","journal-title":"J. Exp. Med"},{"key":"2357_CR17","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/cdd.2012.26","volume":"19","author":"W Li","year":"2012","unstructured":"Li, W. et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ. 19, 1505\u20131513 (2012).","journal-title":"Cell Death Differ."},{"key":"2357_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004992","volume":"4","author":"EL Spaeth","year":"2009","unstructured":"Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 4, e4992 (2009).","journal-title":"PLoS ONE"},{"key":"2357_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/gutjnl-2011-301393","volume":"62","author":"A De Boeck","year":"2013","unstructured":"De Boeck, A. et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1\/HER3 signalling. Gut 62, 550\u2013560 (2013).","journal-title":"Gut"},{"key":"2357_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257\u2013272 (2011).","journal-title":"Cancer Cell"},{"key":"2357_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010088","volume":"5","author":"RS Waterman","year":"2010","unstructured":"Waterman, R. S., Tomchuck, S. L., Henkle, S. L. & Betancourt, A. M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 5, e10088 (2010).","journal-title":"PLoS ONE"},{"key":"2357_CR22","doi-asserted-by":"crossref","unstructured":"Betancourt, A. M. Mesenchymal stem cells\u2014basics and clinical application II. in Advances in Biochemical Engineering\/Biotechnology. Chapter 141, 163\u2013197 (Springer, 2012).","DOI":"10.1007\/10_2012_141"},{"key":"2357_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/ni.3002","volume":"15","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Chen, X., Cao, W. & Shi, Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15, 1009\u20131016 (2014).","journal-title":"Nat. Immunol."},{"key":"2357_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Sensebe, L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824\u2013833 (2018).","journal-title":"Cell Stem Cell"},{"key":"2357_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.tips.2019.07.003","volume":"40","author":"V Gonzalez-Teuber","year":"2019","unstructured":"Gonzalez-Teuber, V. et al. Small molecules to improve ER proteostasis in disease. Trends Pharm. Sci. 40, 684\u2013695 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"2357_CR26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCRESAHA.117.310712","volume":"121","author":"J Bartolucci","year":"2017","unstructured":"Bartolucci, J. et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A Phase 1\/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ. Res. 121, 1192\u20131204 (2017).","journal-title":"Circ. Res."},{"key":"2357_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1182\/blood-2008-12-196287","volume":"114","author":"Y Kong","year":"2009","unstructured":"Kong, Y. et al. The NKG2D ligand ULBP4 binds to TCRgamma9\/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 114, 310\u2013317 (2009).","journal-title":"Blood"},{"key":"2357_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood-2008-04-154138","volume":"113","author":"B Zhang","year":"2009","unstructured":"Zhang, B. et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113, 46\u201357 (2009).","journal-title":"Blood"},{"key":"2357_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1089\/scd.2017.0276","volume":"27","author":"L Fan","year":"2018","unstructured":"Fan, L. et al. miR-450b promotes osteogenic differentiation in vitro and enhances bone formation in vivo by targeting BMP3. Stem Cells Dev. 27, 600\u2013611 (2018).","journal-title":"Stem Cells Dev."},{"key":"2357_CR30","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","volume":"15","author":"M Krampera","year":"2013","unstructured":"Krampera, M. et al. Immunological characterization of multipotent mesenchymal stromal cells\u2013The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054\u20131061 (2013).","journal-title":"Cytotherapy"},{"key":"2357_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315\u2013317 (2006).","journal-title":"Cytotherapy"},{"key":"2357_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","volume":"34","author":"DH Munn","year":"2013","unstructured":"Munn, D. H. & Mellor, A. L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137\u2013143 (2013).","journal-title":"Trends Immunol."},{"key":"2357_CR33","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1182\/blood-2005-10-4077","volume":"107","author":"C Orabona","year":"2006","unstructured":"Orabona, C. et al. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107, 2846\u20132854 (2006).","journal-title":"Blood"},{"key":"2357_CR34","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/stem.1986","volume":"33","author":"M Mounayar","year":"2015","unstructured":"Mounayar, M. et al. PI3kalpha and STAT1 interplay regulates human mesenchymal stem cell immune polarization. Stem Cells 33, 1892\u20131901 (2015).","journal-title":"Stem Cells"},{"key":"2357_CR35","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857\u2013868 (1999).","journal-title":"Cell"},{"key":"2357_CR36","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1182\/blood-2009-12-260711","volume":"116","author":"N Chapuis","year":"2010","unstructured":"Chapuis, N. et al. IkappaB kinase overcomes PI3K\/Akt and ERK\/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood 116, 4240\u20134250 (2010).","journal-title":"Blood"},{"key":"2357_CR37","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1084\/jem.20062105","volume":"204","author":"JP Scott-Browne","year":"2007","unstructured":"Scott-Browne, J. P. et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J. Exp. Med. 204, 2159\u20132169 (2007).","journal-title":"J. Exp. Med."},{"key":"2357_CR38","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1080\/03639045.2016.1225753","volume":"43","author":"HA Moqbel","year":"2017","unstructured":"Moqbel, H. A., ElMeshad, A. N. & El-Nabarawi, M. A. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets. Drug Dev. Ind. Pharm. 43, 742\u2013750 (2017).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"2357_CR39","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1111\/j.1572-0241.1998.00612.x","volume":"93","author":"VM Mishin","year":"1998","unstructured":"Mishin, V. M. et al. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. Am. J. Gastroenterol. 93, 2154\u20132161 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"2357_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7670","volume":"6","author":"G Milan","year":"2015","unstructured":"Milan, G. et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 6, 6670 (2015).","journal-title":"Nat. Commun."},{"key":"2357_CR41","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1172\/JCI90077","volume":"127","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis. J. Clin. Invest 127, 2159\u20132175 (2017).","journal-title":"J. Clin. Invest"},{"key":"2357_CR42","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1182\/blood-2017-07-795278","volume":"131","author":"CD Osswald","year":"2018","unstructured":"Osswald, C. D. et al. Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation. Blood 131, 1556\u20131567 (2018).","journal-title":"Blood"},{"key":"2357_CR43","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.immuni.2016.09.010","volume":"45","author":"C Stienne","year":"2016","unstructured":"Stienne, C. et al. Foxo3 transcription factor drives pathogenic T helper 1 differentiation by inducing the expression of Eomes. Immunity 45, 774\u2013787 (2016).","journal-title":"Immunity"},{"key":"2357_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02183-y","volume":"8","author":"F Flachsbart","year":"2017","unstructured":"Flachsbart, F. et al. Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat. Commun. 8, 2063 (2017).","journal-title":"Nat. Commun."},{"key":"2357_CR45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.stem.2019.02.008","volume":"24","author":"WE Fibbe","year":"2019","unstructured":"Fibbe, W. E. & Shi, Y. FOXO3, a molecular search for the fountain of youth. Cell Stem Cell 24, 351\u2013352 (2019).","journal-title":"Cell Stem Cell"},{"key":"2357_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15903","volume":"8","author":"X Li","year":"2017","unstructured":"Li, X. et al. Ten-eleven translocation 2 interacts with forkhead box O3 and regulates adult neurogenesis. Nat. Commun. 8, 15903 (2017).","journal-title":"Nat. Commun."},{"key":"2357_CR47","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/emboj.2013.186","volume":"32","author":"H Yeo","year":"2013","unstructured":"Yeo, H. et al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J. 32, 2589\u20132602 (2013).","journal-title":"EMBO J."},{"key":"2357_CR48","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1080\/15548627.2016.1203484","volume":"12","author":"MC Gomez-Puerto","year":"2016","unstructured":"Gomez-Puerto, M. C. et al. Activation of autophagy by FOXO3 regulates redox homeostasis during osteogenic differentiation. Autophagy 12, 1804\u20131816 (2016).","journal-title":"Autophagy"},{"key":"2357_CR49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature11895","volume":"494","author":"MR Warr","year":"2013","unstructured":"Warr, M. R. et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 494, 323\u2013327 (2013).","journal-title":"Nature"},{"key":"2357_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nri.2017.118","volume":"18","author":"JA Walker","year":"2018","unstructured":"Walker, J. A. & McKenzie, A. N. J. TH2 cell development and function. Nat. Rev. Immunol. 18, 121\u2013133 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2357_CR51","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd.2018.148","volume":"17","author":"A Sharabi","year":"2018","unstructured":"Sharabi, A. et al. Regulatory T cells in the treatment of disease. Nat. Rev. Drug Discov. 17, 823\u2013844 (2018).","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2357-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:48:14Z","timestamp":1670233694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2357-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,2]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2357-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,2]]},"assertion":[{"value":"27 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"158"}}